Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
The use of alternative funding programs (AFP) has been on the rise in recent years, in keeping with the growing number of self-funded employer health plans. Run by for-profit vendors,…
Our latest research at Norstella strongly suggests that a highly dynamic market access situation in the U.S. is feeding back into upstream decisions around R&D strategy. We explored this topic…
This article was originally published in BioPharma Dive.
Every day, patients are experiencing the life-changing impact of real-world data (RWD), and life sciences companies are feeling the business impact, too.
Manufacturers should be prepared for a period of uncertainty and potential disruption in vaccine policy. The recent overhaul of the CDC’s Advisory Committee on Immunization Practices (ACIP) signals a shift…
In 2024, biotechs were behind almost two-thirds of the FDA’s new drug approvals. Many biotechs are choosing to commercialize their products themselves, rather than partnering with Big Pharma players. Many…
Over the past decade, health systems have seen a rapid influx of private equity, with a six-fold increase in acquisitions totaling $10 trillion. As private equity firms continue to explore…
To speed patient access to potentially life-saving therapies, the FDA established expedited approval pathways for selected drugs that fill unmet needs or treat serious conditions. For patients in need, these…
At the end of April, more than 8,000 attendees visited Las Vegas for the Asembia Specialty Pharmacy Summit, otherwise known as AXS25. If you missed the conference, here’s an overview of…
The landscape of patient access has become increasingly complex, intensified by evolving channel dynamics, greater biosimilar investment, and legislative reform. As payers evolve their utilization management tactics, manufacturers must also…
Established by the Inflation Reduction Act in August 2022, the Medicare Drug Price Negotiation Program is still in its infancy, but is expected to impact a wide swath of stakeholders…
